Results 51 to 60 of about 37,371 (257)
BMC Cardiovascular Disorders, 2022 Background This study aimed to analyze associations between genetic variants and plasma concentrations along with clinical outcomes in dabigatran in patients with non-valvular atrial fibrillation (NVAF).
Zhu Zhu +7 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims To evaluate the effects of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) oestrogen receptor degrader, on the pharmacokinetics of dabigatran (a P‐glycoprotein [P‐gp] substrate) and rosuvastatin (a breast cancer resistance protein [BCRP] substrate).
Derek Z. Yang +9 more
wiley +1 more source
BMC Cardiovascular Disorders, 2020 Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk.
Alexandros Briasoulis +7 more
doaj +1 more source
Neck‐vein thrombosis during spaceflight
British Journal of Clinical Pharmacology, EarlyView.Spaceflight imposes unique environmental challenges, including weightlessness, increased radiation exposure and confinement, which can lead to unexpected health effects. One such example is neck‐vein thrombosis, a condition rarely seen on Earth without predisposing factors such as venous catheters or infections.
Ulrich Limper, Jens Jordan
wiley +1 more source
Primary care management for optimized antithrombotic treatment [PICANT]: study protocol for a cluster-randomized controlled trial [PDF]
, 2012 Background: Antithrombotic treatment is a continuous therapy that is often performed in general practice and requires careful safety management. The aim of this study is to investigate whether a best practice model that applies major elements of case ...
A Siebenhofer +45 more
core +2 more sources
Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations
Clinical and Applied Thrombosis/Hemostasis, 2019 To describe the effect of dabigatran on thrombin time (TT) reagents at different concentrations of thrombin. Pooled normal plasma enriched with dabigatran was dissolved in dimethylsulfoxide (DMSO) at concentrations of 0, 20, 50, 100, 200, 300, and 500 ng/
Xiaoping Xu, Qian Liang
doaj +1 more source
Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. [PDF]
PLoS ONE, 2016 Dabigatran was proven to have similar effect on the prevention of recurrence of venous thromboembolism (VTE) and a lower risk of bleeding compared to vitamin K antagonists (VKA).
J Stevanović +5 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Accurate prediction of oral drug absorption in humans is essential for early drug development; however, physiologically relevant human models are lacking. This study aims to comprehensively assess the EpiIntestinal™, a human primary intestinal 3D model, for its ability to predict oral absorption (Fa), intestinal availability (Fg), CYP3A4 induction, and
Paresh P. Chothe +4 more
wiley +1 more source
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. [PDF]
, 2015 Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke.
Acharya, Tushar, Deedwania, Prakash
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety.
Abdelrahman G. Tawfik +7 more
wiley +1 more source